The most highly anticipated treatments have one thing in common: they’re first-in-class. This is particularly true in the schizophrenia space, Graig Suvannavejh, senior biopharmaceuticals and biotechnology equity research analyst at Mizuho Americas, told BioSpace. “Doctors and patients don’t want ‘me-too’ drugs. They want something new and different.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,